tirzepatide lawsuits Lilly files more to curb sales of counterfeit Mounjaro fda tirzepatide lawsuit Understanding the

These products are not medicines, drugs, or food supplements , and have not been evaluated, approved, or endorsed by any regulatory authority including the MHRA, FDA, or EMA

Kaplan M, Oikonomou CM, Wood CR, Chreifi G, Subramanian P, Ortega DR, et al

Long-term safety data for subcutaneous injection is limited

Key Growth Drivers of the GLP-1 Weight Loss Drug Market Three Structural Catalysts Driving GLP-1 Weight Loss Drug Market Expansion Through 2035 Obesity epidemic scale: More than 1.1 billion adults with obesity globally representing a potential pharmacotherapy patient pool approximately 25 times larger than current GLP-1 prescribing volumes, with only 2.3% of eligible U.S